Using a Blood Test for Alzheimer's Disease
Author Information
Author(s): Monane Mark C, Carlile Robert, Johnson Kim, Gitelman Darren, VandeVrede Lawren, Jacobs Leslie, Braunstein Joel
Primary Institution: C2N Diagnostics
Hypothesis
The study aims to assess the incorporation of the PrecivityAD2™ blood biomarker test into clinical workflows for Alzheimer's disease evaluation.
Conclusion
The study found that healthcare providers reported high acceptance and usefulness of the blood biomarker test for Alzheimer's disease.
Supporting Evidence
- The average acceptance score from healthcare providers was 9.6 out of 10.
- The net promoter score of 75 indicates excellent customer satisfaction.
- The study included 203 patients evaluated by 12 healthcare providers.
Takeaway
Doctors think a new blood test for Alzheimer's is really helpful and easy to use, which could help them make better decisions for their patients.
Methodology
A survey was conducted among healthcare providers using the Technology Acceptance Model to assess the test's usefulness and ease of use.
Participant Demographics
Average age of participants was 74 years, evaluated by 12 healthcare providers from 8 outpatient sites.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website